




PDAB Data Project Presentation  
July 2, 2026

# Drug Cost Review, Affordability Determination, & UPL Cycle



# Proposed Timeline for 2026 Drug Cost Reviews

| May 12                                     | July 2                                                                            | July 31                                                                                 | Aug                                                 | Sept                                                                             | Oct                                                                                          | Nov                      |
|--------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|--------------------------|
| <b>BOARD APPROVES Master List of Drugs</b> | <b>Present Draft Selection Criteria to Board</b><br>for Review and Public Comment | <b>BOARD APPROVES Selection Criteria</b><br>After Review & Discussion of Public Comment | <b>Apply Selection Criteria to Master Drug List</b> | <b>Present Candidate Drug List To Board</b><br>for Discussion and Public Comment | <b>BOARD SELECTS Drugs for Review</b><br>After Board Review and Discussion of Public Comment | <b>Conduct Review(s)</b> |

# **Draft Selection Criteria for Candidate Drug List**

## **SELECTION CRITERIA**

**Total Annual Spend**

**Annual Utilization**

**Cost Per Day of Treatment**

**Cost Per Course of Treatment**

**Patient Out-of-Pocket Cost**

**Annual Percent Increase**

## **OTHER CONSIDERATIONS**

**Minnesota Patient-Identified Drugs**

**Drug Product Characteristics**

# NEXT STEPS FOR 2026

- **July 2 - Present draft Selection Criteria for Board review and public comment**
- **July 31 – Board reviews public comments and approves Selection Criteria**
- **August – Apply Selection Criteria to Master Drug List to create draft Candidate Drug List**
- **September – Present draft Candidate Drug List for Board review and public comment**
- **October – Board reviews public comments and approves Candidate Drug List**
- **November – Begin Cost Reviews**
- **December – Ongoing Cost Reviews**